This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB08908/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n10http://www.rxlist.com/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB08908/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/resource/drugbank/drug/DB08908/identifier/national-drug-code-directory/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08908
rdf:type
n3:Drug
n3:description
Dimethyl fumarate is an anti-inflammatory. It is indicated for multiple sclerosis patients with relapsing forms and is also being investigated for the treatment of psoriasis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera.
n3:dosage
n5:271B5C3E-363D-11E5-9242-09173F13E4C5 n5:271B5C3F-363D-11E5-9242-09173F13E4C5 n5:271B5C3B-363D-11E5-9242-09173F13E4C5 n5:271B5C3C-363D-11E5-9242-09173F13E4C5 n5:271B5C3D-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Papadopoulou A, D'Souza M, Kappos L, Yaldizli O: Dimethyl fumarate for multiple sclerosis. Expert Opin Investig Drugs. 2010 Dec;19(12):1603-12. doi: 10.1517/13543784.2010.534778. Epub 2010 Nov 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21067468 # FDA label.
n3:group
approved investigational
n3:halfLife
MMF has a short half life of about 1 hour, and MMF does not accumulate after repeated doses of dimethyl fumarate.
n3:indication
Used in multiple sclerosis patients with relapsing forms.
owl:sameAs
n8:DB08908
dcterms:title
Dimethyl fumarate
adms:identifier
n14:DB08908 n15:64406-006-02 n16:Dimethyl_fumarate
n3:mechanismOfAction
The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF). MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. As well MMF is an agonist at the nicotinic acid receptor, but the relevance of this is not known.
n3:routeOfElimination
The main route of elimination is by CO2 exhalation that accounts for 60% of the dose. The other minor routes are through the kidney (16% metabolites and trace amounts of unchanged MMF) and the feces (1%).
n3:synonym
1,2-Bis(methoxycarbonyl)-trans-ethylene Dimethyl trans-ethylenedicarboxylate trans-1,2-Ethylenedicarboxylic acid dimethyl ester BG-12 Fumaric acid, dimethyl ester trans-Butenedioic acid dimethyl ester dimethyl (E) butenedioate Tecfidera (e)-But-2-enedioic acid dimethyl ester
n3:toxicity
The most common side effects observed were nausea, diarrhea, abdominal pain, and flushing.
n3:volumeOfDistribution
In healthy people, MMF has a variable volume of distribution of 53 to 73 litres.
n3:foodInteraction
Food does not affect the pharmacokinetics of dimethyl fumarate, but it may reduce dimethyl fumarate induced GI upset and flushing.
n3:proteinBinding
MMF has a plasma protein binding range of 27 to 45%, and the binding is concentration independent.
foaf:page
n10:tecfidera-drug.htm n17:dimethyl-fumarate.html
n3:IUPAC-Name
n4:271B5C44-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5C53-363D-11E5-9242-09173F13E4C5 n4:271B5C42-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5C43-363D-11E5-9242-09173F13E4C5 n4:271B5C40-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5C41-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:N07XX09
n3:H-Bond-Acceptor-Count
n4:271B5C4A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5C4B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5C46-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5C48-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5C47-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5C49-363D-11E5-9242-09173F13E4C5
n3:absorption
Once ingested, dimethyl fumarate is rapidly hydroylyzed by esterases to MMF. Thus there is negligible amount of dimethyl fumarate in the body, and all pharmacokinetic information is quantified with MMF. In multiple sclerosis patients, the time to maximum concentration of MMF is 2 to 2.5 hours and the maximum concentration is 1.87 mg/L.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
624-49-7
n3:category
n3:clearance
MMF clearance was not quantified.
n3:Bioavailability
n4:271B5C4F-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B5C55-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5C51-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5C52-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5C54-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5C4E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5C4D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5C50-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5C45-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5C4C-363D-11E5-9242-09173F13E4C5